drugset / Trial / NCT05662410

Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy

NCT05662410

NaSingle-groupOpen-labelTreatment

Summary

In the present study, investigators attempt to evaluate the short-term, detailed changes in choroidal morphology after three monthly injections of aflibercept in pachychoroid neovasculopathy. The association between these changes and clinical outcomes will be additionally investigated. The primary purpose of this study is to provide reference data regarding the aflibercept-related morphologic changes that implicate structural and functional choroidal alteration, and hence its clinical implications.

Timeline

Start
2022-12-26
Primary completion
2024-05-24
Completion
2024-05-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 0.05 ml Intravitreal
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal